

Equity research, Immunovia: Announced rights issue and pause of coverage

Yesterday, on 28 September, Immunovia announced a partly guaranteed rights issue of units of about SEK 63m initially, with a subscription period from 9 November to 23 November 2026.

As Carlsquare is an advisor on this transaction, our research coverage of Immunovia [is paused](#) until the issue is completed.

Consequently, our previous estimates and valuations for Immunovia no longer apply and will be updated when coverage resumes.

About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. [Read more](#)

Contacts

MARKUS AUGUSTSSON

Head of Equity Research

markus.augustsson@carlsquare.com

+46 (0)76 235 03 20

NIKLAS ELMHAMMER

Senior Equity Analyst

niklas.elmhammer@carlsquare.com

+46 (0)70 898 39 59

Attachments

[Equity research, Immunovia: Announced rights issue and pause of coverage](#)